Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

    Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3

    After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.

      Arpita Dutt headshot

      Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted

      While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.

        Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

        Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

          Arpita Dutt headshot

          5 Biotech and Pharma Stocks with Key FDA Catalysts this November

          Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

            The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens

            The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens

              What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?

              The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.

                Company News For Oct 30, 2017

                Companies in the news are: GILD, AXTA, B, AON

                  Mark Vickery headshot

                  Top Research Reports for JPMorgan Chase, Gilead & ConocoPhillips

                  Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Gilead (GILD) and ConocoPhillips (COP).

                    Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat

                    Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.

                      Benjamin Rains headshot

                      Gilead (GILD) Q3 Earnings and Revenues Sink

                      Gilead Sciences, Inc. (GILD) just released its third-quarter 2017 financial results, posting earnings of $2.06 per share and revenues of $6.51 billion.

                        Is a Beat in Store for Agenus (AGEN) This Earnings Season?

                        Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.

                          Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?

                          Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod

                            Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.

                              Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                              Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.

                                Is Gilead (GILD) Poised for a Beat This Earnings Season?

                                A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

                                  Arpita Dutt headshot

                                  Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

                                  Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?

                                    What's in Store for BioMarin (BMRN) This Earnings Season?

                                    BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

                                      Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval

                                      Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.

                                        Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                                        Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                                          Tracey Ryniec headshot

                                          Where to Find Value in Healthcare Stocks

                                          The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                                            Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                                            Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                                              The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

                                              The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

                                                Arpita Dutt headshot

                                                Pharma Industry Outlook - October 2017

                                                New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.

                                                  Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

                                                  Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.